MIF4GD

Across TCGA pan-cancer cohorts, MIF4GD Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MIF4GD data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MIF4GD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIF4GD expression acts as an unfavorable survival marker.

BLCA, SKCM, and COAD are the cancer types where MIF4GD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
SKCM	DFS	Median	All	0.058	0.757	<.001	12	view →
COAD	OS	Median	II,III,IV	0.202	0.788	.013	6	view →
LUAD	OS	Median	All	0.323	0.834	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MIF4GD–BLCA (OS)

Open the BLCA breakdown →